

Paul E Verweij

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6511466/paul-e-verweij-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

477
papers

24,966
citations

80
h-index

139
g-index

500
ext. papers

29,582
ext. citations

8.1
avg, IF

7.01
L-index

#	Paper	IF	Citations
477	Meanderella rijsii, a new opportunist in the fungal order Pleosporales.. <i>Microbes and Infection</i> , 2022 , 104932	3.2	0
476	A 67-Year-Old Male Patient With COVID-19 With Worsening Respiratory Function and Acute Kidney Failure.. <i>Chest</i> , 2022 , 161, e5-e11	5.3	5
475	Resistance profiling of tolorofim indicates absence of intrinsic resistance and unveils the molecular mechanisms of acquired olorofim resistance.. <i>Emerging Microbes and Infections</i> , 2022 , 1-33	18.9	1
474	Absence of candidemia in critically ill patients with COVID-19 receiving selective digestive decontamination.. <i>Intensive Care Medicine</i> , 2022 , 1	14.5	1
473	Tackling the emerging threat of antifungal resistance to human health.. <i>Nature Reviews Microbiology</i> , 2022 ,	22.2	18
472	Use of Bulk Segregant Analysis for Determining the Genetic Basis of Azole Resistance in the Opportunistic Pathogen .. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022 , 12, 841138	5.9	0
471	Differential Functions of Individual Transcription Factor Binding Sites in the Tandem Repeats Found in Clinically Relevant Promoters in <i>Aspergillus fumigatus</i> .. <i>MBio</i> , 2022 , e0070222	7.8	0
470	Nebulized Amphotericin B in Mechanically Ventilated COVID-19 Patients to Prevent Invasive Pulmonary Aspergillosis: A Retrospective Cohort Study. 2022 , 4, e0696		2
469	Triazole-resistant , an industrially important black spp. used in fermentation in East Asia, isolated from the patient with invasive pulmonary aspergillosis in China.. <i>Emerging Microbes and Infections</i> , 2022 , 1-9	18.9	2
468	Flower Bulb Waste Material is a Natural Niche for the Sexual Cycle in .. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021 , 11, 785157	5.9	1
467	Management of drug-drug interactions of targeted therapies for haematological malignancies and triazole antifungal drugs. <i>Lancet Haematology,the</i> , 2021 ,	14.6	6
466	ESCMID COVID-19 Living guidelines: drug treatment and clinical management. <i>Clinical Microbiology and Infection</i> , 2021 ,	9.5	16
465	Managing secondary fungal infections in severe COVID-19: how to move forward?. <i>Lancet Respiratory Medicine,the</i> , 2021 ,	35.1	2
464	Critical influenza and prophylactic antifungal therapy for aspergillosis: a nuanced approach to a pertinent infectious disease. <i>Intensive Care Medicine</i> , 2021 , 47, 1343-1344	14.5	
463	Multinational Observational Cohort Study of COVID-19-Associated Pulmonary Aspergillosis. <i>Emerging Infectious Diseases</i> , 2021 , 27, 2892-2898	10.2	19
462	Molecular Mechanisms of 5-Fluorocytosine Resistance in Yeasts and Filamentous Fungi. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021 , 7,	5.6	5
461	Phylogenomic Analysis of a 55.1-kb 19-Gene Dataset Resolves a Monophyletic that Includes the Species Complex. <i>Phytopathology</i> , 2021 , 111, 1064-1079	3.8	39

460	ISO standard 20776-1 or serial 2-fold dilution for antifungal susceptibility plate preparation: that is the question!. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 1793-1799	5.1	2
459	Proven <i>Aspergillus flavus</i> pulmonary aspergillosis in a COVID-19 patient: A case report and review of the literature. <i>Mycoses</i> , 2021 , 64, 809-816	5.2	4
458	Chlorhexidine for the Treatment of Keratitis: A Case Series and Mini Review. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021 , 7,	5.6	2
457	Identifying Conserved Generic spp. Co-Expressed Gene Modules Associated with Germination Using Cross-Platform and Cross-Species Transcriptomics. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021 , 7,	5.6	1
456	Triazole-Resistance in Environmental in Latin American and African Countries. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021 , 7,	5.6	4
455	Chronic HIV infection induces transcriptional and functional reprogramming of innate immune cells. <i>JCI Insight</i> , 2021 , 6,	9.9	12
454	A world-wide analysis of reduced sensitivity to DMI fungicides in the banana pathogen <i>Pseudocercospora fijiensis</i> . <i>Pest Management Science</i> , 2021 , 77, 3273-3288	4.6	1
453	Potency of olorofim (F901318) compared to contemporary antifungal agents against clinical isolates, and review of azole resistance phenotype and genotype epidemiology in China. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 ,	5.9	2
452	Neuraminidase and SIGLEC15 modulate the host defense against pulmonary aspergillosis. <i>Cell Reports Medicine</i> , 2021 , 2, 100289	18	7
451	Implementation of rapid diagnostics assays for detection of histoplasmosis and cryptococcosis in central american people living with HIV. <i>Mycoses</i> , 2021 , 64, 1396-1401	5.2	5
450	Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a randomised, open-label, proof-of-concept trial. <i>Intensive Care Medicine</i> , 2021 , 47, 674-686	14.5	18
449	Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis. <i>Intensive Care Medicine</i> , 2021 , 47, 819-834	14.5	30
448	Diagnostic dilemma in COVID-19-associated pulmonary aspergillosis - AuthorsPreply. <i>Lancet Infectious Diseases, The</i> , 2021 , 21, 767-769	25.5	3
447	Case series of four secondary mucormycosis infections in COVID-19 patients, the Netherlands, December 2020 to May 2021. <i>Eurosurveillance</i> , 2021 , 26,	19.8	25
446	A mould infection in disguise. <i>Clinical Microbiology and Infection</i> , 2021 , 27, 854-855	9.5	1
445	Azole-Resistance Development; How the Lifecycle Defines the Potential for Adaptation. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021 , 7,	5.6	5
444	COVID-19-associated <i>Aspergillus</i> tracheobronchitis: the interplay between viral tropism, host defence, and fungal invasion. <i>Lancet Respiratory Medicine, the</i> , 2021 , 9, 795-802	35.1	21
443	Ventilator-associated pneumonia involving in a patient with coronavirus disease 2019 (COVID-19) from Argentina. <i>Medical Mycology Case Reports</i> , 2021 , 31, 19-23	1.7	19

442	Fungal infections should be part of the core outcome set for COVID-19. <i>Lancet Infectious Diseases, The</i> , 2021 , 21, e145	25.5	6
441	Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. <i>Lancet Infectious Diseases, The</i> , 2021 , 21, e149-e162	25.5	242
440	Regional Differences in Antifungal Susceptibility of the Prevalent Dermatophyte <i>Trichophyton rubrum</i> . <i>Mycopathologia</i> , 2021 , 186, 53-70	2.9	4
439	Dynamics of <i>Aspergillus fumigatus</i> in Azole Fungicide-Containing Plant Waste in the Netherlands (2016-2017). <i>Applied and Environmental Microbiology</i> , 2021 , 87,	4.8	8
438	Genetic and Phenotypic Characterization of in-Host Developed Azole-Resistant Isolates. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021 , 7,	5.6	1
437	Defining Galactomannan Positivity in the Updated EORTC/MSGERC Consensus Definitions of Invasive Fungal Diseases. <i>Clinical Infectious Diseases</i> , 2021 , 72, S89-S94	11.6	5
436	Antifungal Susceptibility and Mutations in the Squalene Epoxidase Gene in Dermatophytes of the <i>Trichophyton mentagrophytes</i> Species Complex. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , 65, e0005821	5.9	6
435	Global guideline for the diagnosis and management of the endemic mycoses: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology. <i>Lancet Infectious Diseases, The</i> , 2021 , 21, e364-e374	25.5	16
434	Invasive pulmonary aspergillosis associated with viral pneumonitis. <i>Current Opinion in Microbiology</i> , 2021 , 62, 21-27	7.9	8
433	<i>Aspergillus</i> Test Profiles and Mortality in Critically Ill COVID-19 Patients. <i>Journal of Clinical Microbiology</i> , 2021 , 59, e0122921	9.7	15
432	When to change treatment of acute invasive aspergillosis: an expert viewpoint. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 ,	5.1	5
431	Stable prevalence of triazole-resistance in <i>Aspergillus fumigatus</i> complex clinical isolates in a Belgian tertiary care center from 2016 to 2020. <i>Journal of Infection and Chemotherapy</i> , 2021 , 27, 1774-1778	2.2	1
430	Fungal keratitis caused by <i>Pseudallescheria boydii</i> : clinical and mycological characteristics. <i>Journal of Ophthalmic Inflammation and Infection</i> , 2021 , 11, 30	2.3	1
429	<i>Aspergillus fumigatus</i> tryptophan metabolic route differently affects host immunity. <i>Cell Reports</i> , 2021 , 34, 108673	10.6	4
428	First Case of Rhinocerebral Mucormycosis Caused by <i>Lichtheimia ornata</i> , with a Review of <i>Lichtheimia</i> Infections. <i>Mycopathologia</i> , 2020 , 185, 555-567	2.9	6
427	Gene Mutation Prevalence in Triazole-Resistant Clinical Isolates. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020 , 6,	5.6	6
426	Diagnosing COVID-19-associated pulmonary aspergillosis. <i>Lancet Microbe, The</i> , 2020 , 1, e53-e55	22.2	115
425	COVID-19-associated Pulmonary Aspergillosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 202, 132-135	10.2	194

424	Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. <i>Intensive Care Medicine</i> , 2020 , 46, 1524-1535	14.5	149
423	Paradoxal Trends in Azole-Resistant <i>Aspergillus fumigatus</i> in a National Multicenter Surveillance Program, the Netherlands, 2013-2018. <i>Emerging Infectious Diseases</i> , 2020 , 26, 1447-1455	10.2	26
422	Evaluation of a New Culture Protocol for Enhancing Fungal Detection Rates in Respiratory Samples of Cystic Fibrosis Patients. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020 , 6,	5.6	3
421	In vitro interaction of isavuconazole and anidulafungin against azole-susceptible and azole-resistant <i>Aspergillus fumigatus</i> isolates. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 2582-2586 ¹	5.1	1
420	European confederation of medical mycology expert consult-An ECMM excellence center initiative. <i>Mycoses</i> , 2020 , 63, 566-572	5.2	2
419	International survey on influenza-associated pulmonary aspergillosis (IAPA) in intensive care units: responses suggest low awareness and potential underdiagnosis outside Europe. <i>Critical Care</i> , 2020 , 24, 84	10.8	17
418	<i>Aspergillus fumigatus</i> and pan-azole resistance: who should be concerned?. <i>Current Opinion in Infectious Diseases</i> , 2020 , 33, 290-297	5.4	25
417	Clinical relevance of <i>Scedosporium</i> spp. and <i>Exophiala dermatitidis</i> in patients with cystic fibrosis: A nationwide study. <i>Medical Mycology</i> , 2020 , 58, 859-866	3.9	6
416	Comparison of MIC Test Strip and Sensititre YeastOne with the CLSI and EUCAST Broth Microdilution Reference Methods for Antifungal Susceptibility Testing of <i>Cryptococcus neoformans</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	2
415	Implications for IV posaconazole dosing in the era of obesity. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 1006-1013	5.1	10
414	Reply to Mafaciolli and Pasqualotto. <i>Clinical Infectious Diseases</i> , 2020 , 71, 2542-2543	11.6	1
413	Molecular Mechanisms of Conidial Germination in spp. <i>Microbiology and Molecular Biology Reviews</i> , 2020 , 84,	13.2	27
412	Pharmacokinetics and Pharmacodynamics of Posaconazole. <i>Drugs</i> , 2020 , 80, 671-695	12.1	29
411	Surveillance of catheter-related bloodstream infections in haemato-oncology patients: comparison of two definitions. <i>Journal of Hospital Infection</i> , 2020 , 105, 686-690	6.9	0
410	1598. Clinical implications of azole-resistant vs. azole-susceptible invasive aspergillosis in hematological malignancy (CLARITY) ¹ multicenter study. <i>Open Forum Infectious Diseases</i> , 2020 , 7, S795-S796	5.1	1
409	Antifungal Activity of Antimicrobial Peptides and Proteins against. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020 , 6,	5.6	4
408	-specific antibodies in patients with chronic tuberculosis. <i>International Journal of Tuberculosis and Lung Disease</i> , 2020 , 24, 853-856	2.1	0
407	High-dose posaconazole for azole-resistant aspergillosis and other difficult-to-treat mould infections. <i>Mycoses</i> , 2020 , 63, 122-130	5.2	27

406	High Azole Resistance in <i>Aspergillus fumigatus</i> Isolates from Strawberry Fields, China, 2018. <i>Emerging Infectious Diseases</i> , 2020 , 26, 81-89	10.2	23
405	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. <i>Clinical Infectious Diseases</i> , 2020 , 71, 1367-1376	11.6	607
404	Does Pulmonary Aspergillosis Complicate Coronavirus Disease 2019? 2020 , 2, e0211		7
403	Reply to Fekkar : Fungal Infection during COVID-19: Does Mean Secondary Invasive Aspergillosis?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 202, 903-904	10.2	2
402	A Multidisciplinary Approach to Fungal Infections: One-Year Experiences of a Center of Expertise in Mycology. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020 , 6,	5.6	4
401	Coronavirus Disease 2019 (COVID-19) in a Patient with Disseminated Histoplasmosis and HIV-A Case Report from Argentina and Literature Review. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020 , 6,	5.6	20
400	The Medical Triazole Voriconazole Can Select for Tandem Repeat Variations in Azole-Resistant Harboring TR/L98H Via Asexual Reproduction. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020 , 6,	5.6	3
399	The one health problem of azole resistance in <i>Aspergillus fumigatus</i> : current insights and future research agenda. <i>Fungal Biology Reviews</i> , 2020 , 34, 202-214	6.8	30
398	No to : Phylogenomic and Practical Reasons for Continued Inclusion of the <i>Fusarium solani</i> Species Complex in the Genus. <i>MSphere</i> , 2020 , 5,	5	32
397	Contact lens-related fungal keratitis. <i>Lancet Infectious Diseases, The</i> , 2020 , 20, 1100	25.5	3
396	Update on Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry Identification of Filamentous Fungi. <i>Journal of Clinical Microbiology</i> , 2020 , 58,	9.7	17
395	Parasexual recombination enables to persist in cystic fibrosis. <i>ERJ Open Research</i> , 2020 , 6,	3.5	6
394	Influenza Coinfection: Be(a)ware of Invasive Aspergillosis. <i>Clinical Infectious Diseases</i> , 2020 , 70, 349-350	11.6	11
393	Lateral flow assays for diagnosing invasive pulmonary aspergillosis in adult hematology patients: A comparative multicenter study. <i>Medical Mycology</i> , 2020 , 58, 444-452	3.9	38
392	Epidemiology and Clinical Management of keratitis in the Netherlands, 2005-2016. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020 , 10, 133	5.9	15
391	Burden of serious fungal infections in the Netherlands. <i>Mycoses</i> , 2020 , 63, 625-631	5.2	15
390	Mutations, Extrolite Profiles, and Antifungal Susceptibility in Clinical and Environmental Isolates of the <i>Aspergillus viridinutans</i> Species Complex. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	9
389	The fading boundaries between patient and environmental routes of triazole resistance selection in <i>Aspergillus fumigatus</i> . <i>PLoS Pathogens</i> , 2019 , 15, e1007858	7.6	24

388	Environmental Hotspots for Azole Resistance Selection of <i>Aspergillus fumigatus</i> , the Netherlands. <i>Emerging Infectious Diseases</i> , 2019 , 25, 1347-1353	10.2	55
387	Prevalence of voriconazole-resistant invasive aspergillosis and its impact on mortality in haematology patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 2759-2766	5.1	32
386	Recreation of in-host acquired single nucleotide polymorphisms by CRISPR-Cas9 reveals an uncharacterised gene playing a role in <i>Aspergillus fumigatus</i> azole resistance via a non-cyp51A mediated resistance mechanism. <i>Fungal Genetics and Biology</i> , 2019 , 130, 98-106	3.9	17
385	Raw genome sequence data for 13 isogenic strains isolated over a 2 year period from a patient with chronic granulomatous disease. <i>Data in Brief</i> , 2019 , 25, 104021	1.2	5
384	Activity of Chlorhexidine Compared with Seven Antifungal Agents against 98 Isolates Recovered from Fungal Keratitis Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	14
383	Aspergillosis related to severe influenza: A worldwide phenomenon?. <i>Clinical Respiratory Journal</i> , 2019 , 13, 540-542	1.7	6
382	Aerosol Transmission of <i>Aspergillus fumigatus</i> in Cystic Fibrosis Patients in the Netherlands. <i>Emerging Infectious Diseases</i> , 2019 , 25, 797-799	10.2	24
381	Nontuberculous mycobacterial pulmonary disease and co-infection: Bonnie and Clyde?. <i>European Respiratory Journal</i> , 2019 , 54,	13.6	8
380	Relevance of heterokaryosis for adaptation and azole-resistance development in <i>Aspergillus fumigatus</i> . <i>Proceedings of the Royal Society B: Biological Sciences</i> , 2019 , 286, 20182886	4.4	8
379	Triazole Antifungal Susceptibility Patterns among Species in QuBec, Canada. <i>Journal of Clinical Microbiology</i> , 2019 , 57,	9.7	1
378	Triazole resistance in <i>Aspergillus fumigatus</i> : recent insights and challenges for patient management. <i>Clinical Microbiology and Infection</i> , 2019 , 25, 799-806	9.5	76
377	Diagnostic-driven management of invasive fungal disease in hematology in the era of prophylaxis and resistance emergence: Dutch courage?. <i>Medical Mycology</i> , 2019 , 57, S267-S273	3.9	1
376	Facilitators of adaptation and antifungal resistance mechanisms in clinically relevant fungi. <i>Fungal Genetics and Biology</i> , 2019 , 132, 103254	3.9	26
375	ECMM CandiReg-A ready to use platform for outbreaks and epidemiological studies. <i>Mycoses</i> , 2019 , 62, 920-927	5.2	10
374	A Comparison of Isolation Methods for Black Fungi Degrading Aromatic Toxins. <i>Mycopathologia</i> , 2019 , 184, 653-660	2.9	10
373	External Quality Assessment Evaluating the Ability of Dutch Clinical Microbiological Laboratories to Identify. <i>Journal of Fungi (Basel, Switzerland)</i> , 2019 , 5,	5.6	9
372	2268. Clinical Implications of Azole-Resistant vs. Azole-Susceptible Invasive Aspergillosis in Hematological Malignancy (CLARITY): A Multicenter Study. <i>Open Forum Infectious Diseases</i> , 2019 , 6, S776 ¹ -S776 ⁷⁸		
371	In-vitro antifungal susceptibility testing of itraconazole and luliconazole against <i>Aspergillus flavus</i> as an important agent of invasive aspergillosis. <i>Journal of Infection and Chemotherapy</i> , 2019 , 25, 157-160 ^{2.2}		10

370	Trends in Azole Resistance in <i>Aspergillus fumigatus</i> , the Netherlands, 1994-2016. <i>Emerging Infectious Diseases</i> , 2019 , 25, 176-178	10.2	29
369	Diagnosing Invasive Pulmonary Aspergillosis in Hematology Patients: a Retrospective Multicenter Evaluation of a Novel Lateral Flow Device. <i>Journal of Clinical Microbiology</i> , 2019 , 57,	9.7	14
368	Phenotypic plasticity and the evolution of azole resistance in <i>Aspergillus fumigatus</i> ; an expression profile of clinical isolates upon exposure to itraconazole. <i>BMC Genomics</i> , 2019 , 20, 28	4.5	16
367	How to: EUCAST recommendations on the screening procedure E.Def 10.1 for the detection of azole resistance in <i>Aspergillus fumigatus</i> isolates using four-well azole-containing agar plates. <i>Clinical Microbiology and Infection</i> , 2019 , 25, 681-687	9.5	42
366	Prevalence and diversity of filamentous fungi in the airways of cystic fibrosis patients - A Dutch, multicentre study. <i>Journal of Cystic Fibrosis</i> , 2019 , 18, 221-226	4.1	36
365	Voriconazole Resistance and Mortality in Invasive Aspergillosis: A Multicenter Retrospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2019 , 68, 1463-1471	11.6	105
364	Epidemiology of <i>Aspergillus</i> species causing keratitis in Mexico. <i>Mycoses</i> , 2019 , 62, 144-151	5.2	12
363	Elevated MIC Values of Imidazole Drugs against <i>Aspergillus fumigatus</i> Isolates with TR/L98H/S297T/F495I Mutation. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	21
362	<i>Fusarium metavorans</i> sp. nov.: The frequent opportunist FSSC6P. <i>Medical Mycology</i> , 2018 , 56, 144-152	3.9	11
361	Epidemiology of invasive aspergillosis and triazole-resistant <i>Aspergillus fumigatus</i> in patients with haematological malignancies: a single-centre retrospective cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 1389-1394	5.1	19
360	Gene co-expression analysis identifies gene clusters associated with isotropic and polarized growth in <i>Aspergillus fumigatus</i> conidia. <i>Fungal Genetics and Biology</i> , 2018 , 116, 62-72	3.9	17
359	The diagnosis and treatment of invasive aspergillosis in Dutch haematology units facing a rapidly increasing prevalence of azole-resistance. A nationwide survey and rationale for the DB-MSG 002 study protocol. <i>Mycoses</i> , 2018 , 61, 656-664	5.2	17
358	Diagnosis and management of <i>Aspergillus</i> diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. <i>Clinical Microbiology and Infection</i> , 2018 , 24 Suppl 1, e1-e38	9.5	584
357	In-host microevolution of <i>Aspergillus fumigatus</i> : A phenotypic and genotypic analysis. <i>Fungal Genetics and Biology</i> , 2018 , 113, 1-13	3.9	48
356	Combination of Amphotericin B and Terbinafine against Melanized Fungi Associated with Chromoblastomycosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	9
355	Triazole resistance surveillance in <i>Aspergillus fumigatus</i> . <i>Medical Mycology</i> , 2018 , 56, 83-92	3.9	77
354	Current antifungal treatment of fusariosis. <i>International Journal of Antimicrobial Agents</i> , 2018 , 51, 326-332.3		54
353	Isavuconazole susceptibility of clinical <i>Aspergillus fumigatus</i> isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 134-142	5.1	21

352	Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. <i>Lancet Respiratory Medicine</i> , 2018 , 6, 782-792	35.1	379
351	Molecular Detection of Azole-Resistant in Clinical Samples. <i>Frontiers in Microbiology</i> , 2018 , 9, 515	5.7	24
350	Methodologies for and evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms. <i>Microbial Cell</i> , 2018 , 5, 300-326	3.9	57
349	Discovery and characterization of novel <i>Aspergillus fumigatus</i> mycoviruses. <i>PLoS ONE</i> , 2018 , 13, e02005317	3.7	27
348	Epidemiology and aetiologies of cryptococcal meningitis in Africa, 1950-2017: protocol for a systematic review. <i>BMJ Open</i> , 2018 , 8, e020654	3	12
347	Clinical Pharmacokinetics and Pharmacodynamics of Micafungin. <i>Clinical Pharmacokinetics</i> , 2018 , 57, 267-286	6.2	36
346	Genotyping of in Formalin-Fixed Paraffin-Embedded Tissues and Serum Samples From Patients With Invasive Aspergillosis. <i>Frontiers in Cellular and Infection Microbiology</i> , 2018 , 8, 377	5.9	4
345	Invasive pulmonary aspergillosis complicating severe influenza: epidemiology, diagnosis and treatment. <i>Current Opinion in Infectious Diseases</i> , 2018 , 31, 471-480	5.4	86
344	Itraconazole, Voriconazole, and Posaconazole CLSI MIC Distributions for Wild-Type and Azole-Resistant Isolates. <i>Journal of Fungi (Basel, Switzerland)</i> , 2018 , 4,	5.6	27
343	Antifungal Use in Veterinary Practice and Emergence of Resistance 2018 , 359-402		6
342	Absent in vitro interaction between chloroquine and antifungals against <i>Aspergillus fumigatus</i> . <i>Clinical Microbiology and Infection</i> , 2017 , 23, 679-681	9.5	1
341	Population Pharmacokinetic Model and Pharmacokinetic Target Attainment of Micafungin in Intensive Care Unit Patients. <i>Clinical Pharmacokinetics</i> , 2017 , 56, 1197-1206	6.2	19
340	Fever and arthralgia after Volcano boarding in Nicaragua. <i>Travel Medicine and Infectious Disease</i> , 2017 , 16, 68-69	8.4	2
339	Genetic Diversity and Antifungal Susceptibility of 200 Clinical and Environmental <i>Aspergillus flavus</i> Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	25
338	Personalized medicine in influenza: a bridge too far or the near future?. <i>Current Opinion in Pulmonary Medicine</i> , 2017 , 23, 237-240	3	3
337	Efficacy of Liposomal Amphotericin B against Wild-Type and Azole-Resistant <i>Aspergillus fumigatus</i> Isolates in Two Different Immunosuppression Models of Invasive Aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	5
336	Susceptibility Testing of Common and Uncommon <i>Aspergillus</i> Species against Posaconazole and Other Mold-Active Antifungal Azoles Using the Sensitre Method. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	19
335	In vitro activity of the novel antifungal compound F901318 against difficult-to-treat <i>Aspergillus</i> isolates. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 2548-2552	5.1	56

334	Successful treatment of azole-resistant invasive aspergillosis in a bottlenose dolphin with high-dose posaconazole. <i>Medical Mycology Case Reports</i> , 2017 , 16, 16-19	1.7	13
333	Influenza-Associated Aspergillosis in Critically Ill Patients. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 196, 524-527	10.2	127
332	Changes in In Vitro Susceptibility Patterns of Aspergillus to Triazoles and Correlation With Aspergillosis Outcome in a Tertiary Care Cancer Center, 1999-2015. <i>Clinical Infectious Diseases</i> , 2017 , 65, 216-225	11.6	39
331	In Vitro Antifungal Susceptibility Profiles of 12 Antifungal Drugs against 55 Trichophyton schoenleinii Isolates from Tinea Capitis Favosa Patients in Iran, Turkey, and China. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	14
330	Itraconazole or Amphotericin B for Talaromycosis. <i>New England Journal of Medicine</i> , 2017 , 377, 1402-1403	39.2	2
329	Animal Models for Studying Triazole Resistance in Aspergillus fumigatus. <i>Journal of Infectious Diseases</i> , 2017 , 216, S466-S473	7	11
328	Multicentre validation of 4-well azole agar plates as a screening method for detection of clinically relevant azole-resistant Aspergillus fumigatus. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 3325-3333	5.1	32
327	Antifungal Susceptibility Testing of Fusarium: A Practical Approach. <i>Journal of Fungi (Basel, Switzerland)</i> , 2017 , 3,	5.6	32
326	Single-Center Evaluation of an Agar-Based Screening for Azole Resistance in Aspergillus fumigatus by Using VIPcheck. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	29
325	Evolution of cross-resistance to medical triazoles in through selection pressure of environmental fungicides. <i>Proceedings of the Royal Society B: Biological Sciences</i> , 2017 , 284,	4.4	30
324	Importance of Resolving Fungal Nomenclature: the Case of Multiple Pathogenic Species in the Genus. <i>MSphere</i> , 2017 , 2,	5	74
323	Flucloxacillin Results in Suboptimal Plasma Voriconazole Concentrations. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	13
322	Molecular Diagnosis of Invasive Aspergillosis and Detection of Azole Resistance by a Newly Commercialized PCR Kit. <i>Journal of Clinical Microbiology</i> , 2017 , 55, 3210-3218	9.7	44
321	Triazole phenotypes and genotypic characterization of clinical Aspergillus fumigatus isolates in China. <i>Emerging Microbes and Infections</i> , 2017 , 6, e109	18.9	19
320	A Novel Environmental Azole Resistance Mutation in and a Possible Role of Sexual Reproduction in Its Emergence. <i>MBio</i> , 2017 , 8,	7.8	79
319	Spectrophotometric reading of EUCAST antifungal susceptibility testing of Aspergillus fumigatus. <i>Clinical Microbiology and Infection</i> , 2017 , 23, 98-103	9.5	13
318	Evaluation of MIC Strip Isavuconazole Test for Susceptibility Testing of Wild-Type and Non-Wild-Type Aspergillus fumigatus Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	12
317	Systemic Antifungal Agents: Current Status and Projected Future Developments. <i>Methods in Molecular Biology</i> , 2017 , 1508, 107-139	1.4	32

316	Azole Resistance in <i>Aspergillus fumigatus</i> : Mechanisms, Route of Resistance Selection, and Clinical Implications 2017 , 403-421		4
315	Effect of involved <i>Aspergillus</i> species on galactomannan in bronchoalveolar lavage of patients with invasive aspergillosis. <i>Journal of Medical Microbiology</i> , 2017 , 66, 898-904	3.2	20
314	Azole Resistance in <i>Aspergillus fumigatus</i> : Can We Retain the Clinical Use of Mold-Active Antifungal Azoles?. <i>Clinical Infectious Diseases</i> , 2016 , 62, 362-8	11.6	372
313	Azole resistance surveillance in <i>Aspergillus fumigatus</i> : beneficial or biased?. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 2079-82	5.1	39
312	In-host adaptation and acquired triazole resistance in <i>Aspergillus fumigatus</i> : a dilemma for clinical management. <i>Lancet Infectious Diseases</i> , 2016 , 16, e251-e260	25.5	85
311	Discrimination of Aspergillosis, Mucormycosis, Fusariosis, and Scedosporiosis in Formalin-Fixed Paraffin-Embedded Tissue Specimens by Use of Multiple Real-Time Quantitative PCR Assays. <i>Journal of Clinical Microbiology</i> , 2016 , 54, 2798-2803	9.7	55
310	Next-Generation Sequencing in the Mycology Lab. <i>Current Fungal Infection Reports</i> , 2016 , 10, 37-42	1.4	32
309	Combination of Amphotericin B and Flucytosine against Neurotropic Species of Melanized Fungi Causing Primary Cerebral Phaeohyphomycosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 2346-51	5.9	16
308	Dose Reduction of Caspofungin in Intensive Care Unit Patients with Child Pugh B Will Result in Suboptimal Exposure. <i>Clinical Pharmacokinetics</i> , 2016 , 55, 723-33	6.2	27
307	Quantitative Analysis of Single-Nucleotide Polymorphism for Rapid Detection of TR34/L98H- and TR46/Y121F/T289A-Positive <i>Aspergillus fumigatus</i> Isolates Obtained from Patients in Iran from 2010 to 2014. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 387-92	5.9	16
306	Emerging aspergillosis by azole-resistant <i>Aspergillus fumigatus</i> at an intensive care unit in the Netherlands, 2010 to 2013. <i>Eurosurveillance</i> , 2016 , 21,	19.8	46
305	Azole Resistance of <i>Aspergillus fumigatus</i> in Immunocompromised Patients with Invasive Aspergillosis. <i>Emerging Infectious Diseases</i> , 2016 , 22, 158-9	10.2	22
304	Diagnosis and management of aspergillosis in the Netherlands: a national survey. <i>Mycoses</i> , 2016 , 59, 101-7	5.2	33
303	Decreased Cell Wall Galactosaminogalactan in <i>Aspergillus nidulans</i> Mediates Dysregulated Inflammation in the Chronic Granulomatous Disease Host. <i>Journal of Interferon and Cytokine Research</i> , 2016 , 36, 488-98	3.5	13
302	Clinical implications of globally emerging azole resistance in <i>Aspergillus fumigatus</i> . <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2016 , 371,	5.8	160
301	Voriconazole-Susceptible and Voriconazole-Resistant <i>Aspergillus fumigatus</i> Coinfection. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016 , 193, 927-9	10.2	30
300	Are the TR46/Y121F/T289A Mutations in Azole-Resistant Aspergillosis Patient Acquired or Environmental?. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 3259-60	5.9	11
299	Optimizing antifungal strategies to improve patient survival. <i>Future Microbiology</i> , 2016 , 11, 1211-1215	2.9	4

298	Epidemiology and Molecular Characterizations of Azole Resistance in Clinical and Environmental <i>Aspergillus fumigatus</i> Isolates from China. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 5878-84	5.9	45
297	Genotype-phenotype complexity of the TR46/Y121F/T289A cyp51A azole resistance mechanism in <i>Aspergillus fumigatus</i> . <i>Fungal Genetics and Biology</i> , 2015 , 82, 129-35	3.9	65
296	De novo induction of resistance against voriconazole in <i>Aspergillus fumigatus</i> . <i>Journal of Global Antimicrobial Resistance</i> , 2015 , 3, 52-53	3.4	1
295	Neglected fungal zoonoses: hidden threats to man and animals. <i>Clinical Microbiology and Infection</i> , 2015 , 21, 416-25	9.5	32
294	High-Level Pan-Azole-Resistant Aspergillosis. <i>Journal of Clinical Microbiology</i> , 2015 , 53, 2343-5	9.7	16
293	Altered Micafungin Pharmacokinetics in Intensive Care Unit Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 4403-9	5.9	40
292	Pharmacodynamics of isavuconazole in an <i>Aspergillus fumigatus</i> mouse infection model. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 2855-66	5.9	52
291	Posaconazole prophylaxis in experimental azole-resistant invasive pulmonary aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 1487-94	5.9	19
290	Prospective multicenter international surveillance of azole resistance in <i>Aspergillus fumigatus</i> . <i>Emerging Infectious Diseases</i> , 2015 , 21, 1041-4	10.2	238
289	Multi-triazole-resistant <i>Aspergillus fumigatus</i> infections in Australia. <i>Mycoses</i> , 2015 , 58, 350-5	5.2	77
288	Emergence of fusarioses in a university hospital in Turkey during a 20-year period. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2015 , 34, 1683-91	5.3	27
287	International expert opinion on the management of infection caused by azole-resistant <i>Aspergillus fumigatus</i> . <i>Drug Resistance Updates</i> , 2015 , 21-22, 30-40	23.2	210
286	<i>Aspergillus</i> and aspergilloses in wild and domestic animals: a global health concern with parallels to human disease. <i>Medical Mycology</i> , 2015 , 53, 765-97	3.9	111
285	Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and <i>Aspergillus fumigatus</i> in an in vitro pharmacokinetic/pharmacodynamic model--authors' response. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 634-5	5.1	4
284	Azole, polyene and echinocandin MIC distributions for wild-type, TR34/L98H and TR46/Y121F/T289A <i>Aspergillus fumigatus</i> isolates in the Netherlands. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 178-81	5.1	73
283	Asexual sporulation facilitates adaptation: The emergence of azole resistance in <i>Aspergillus fumigatus</i> . <i>Evolution; International Journal of Organic Evolution</i> , 2015 , 69, 2573-86	3.8	28
282	The strength of synergistic interaction between posaconazole and caspofungin depends on the underlying azole resistance mechanism of <i>Aspergillus fumigatus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 1738-44	5.9	20
281	First description of azole-resistant <i>Aspergillus fumigatus</i> due to TR46/Y121F/T289A mutation in France. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 4331-5	5.9	51

280	Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases. <i>Expert Review of Anti-Infective Therapy</i> , 2015 , 13, 9-27	5.5	34
279	In vitro antifungal susceptibility of <i>Trichophyton violaceum</i> isolated from tinea capitis patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 1072-5	5.1	7
278	Azole Resistance in <i>Aspergillus fumigatus</i> : Mechanisms, Route of Resistance Selection, and Clinical Implications 2015 , 1-17		2
277	Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and <i>Aspergillus fumigatus</i> in an in vitro pharmacokinetic/pharmacodynamic model. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 1611-9	5.1	23
276	ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi. <i>Clinical Microbiology and Infection</i> , 2014 , 20 Suppl 3, 47-75	9.5	207
275	Susceptibility breakpoints for amphotericin B and <i>Aspergillus</i> species in an in vitro pharmacokinetic-pharmacodynamic model simulating free-drug concentrations in human serum. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 2356-62	5.9	14
274	Incidence of and risk factors for persistent gram-positive bacteraemia and catheter-related thrombosis in haematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2014 , 49, 264-9	4.4	13
273	Pharmacokinetics of caspofungin in ICU patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 3294-9	5.1	52
272	Black yeasts and their filamentous relatives: principles of pathogenesis and host defense. <i>Clinical Microbiology Reviews</i> , 2014 , 27, 527-42	34	69
271	The role of azoles in the management of azole-resistant aspergillosis: from the bench to the bedside. <i>Drug Resistance Updates</i> , 2014 , 17, 37-50	23.2	74
270	Screening of the central nervous system in children with invasive pulmonary aspergillosis. <i>Medical Mycology Case Reports</i> , 2014 , 4, 8-11	1.7	12
269	Occurrence of azole-resistant species of <i>Aspergillus</i> in the UK environment. <i>Journal of Global Antimicrobial Resistance</i> , 2014 , 2, 276-279	3.4	36
268	Multi-azole-resistant <i>Aspergillus fumigatus</i> in the environment in Tanzania. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 2979-83	5.1	106
267	Intrapulmonary posaconazole penetration at the infection site in an immunosuppressed murine model of invasive pulmonary aspergillosis receiving oral prophylactic regimens. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 2964-7	5.9	11
266	Antifungal susceptibility patterns of opportunistic fungi in the genera <i>Verruconis</i> and <i>Ochroconis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 3285-92	5.9	18
265	Continuous infusion of amphotericin B deoxycholate for the treatment of life-threatening <i>Candida</i> infections. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013 , 188, 1033	10.2	2
264	Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis. <i>Expert Review of Anti-Infective Therapy</i> , 2013 , 11, 931-41	5.5	56
263	Triazole fungicides and the selection of resistance to medical triazoles in the opportunistic mould <i>Aspergillus fumigatus</i> . <i>Pest Management Science</i> , 2013 , 69, 165-70	4.6	49

262	Aspergillosis due to voriconazole highly resistant <i>Aspergillus fumigatus</i> and recovery of genetically related resistant isolates from domiciles. <i>Clinical Infectious Diseases</i> , 2013 , 57, 513-20	11.6	248
261	Inhibitory and fungicidal effects of antifungal drugs against <i>Aspergillus</i> species in the presence of serum. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 1625-31	5.9	18
260	Azole-resistant <i>Aspergillus fumigatus</i> , Iran. <i>Emerging Infectious Diseases</i> , 2013 , 19, 832-4	10.2	50
259	In vitro interaction of voriconazole and anidulafungin against triazole-resistant <i>Aspergillus fumigatus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 796-803	5.9	32
258	Pharmacodynamics and dose-response relationships of liposomal amphotericin B against different azole-resistant <i>Aspergillus fumigatus</i> isolates in a murine model of disseminated aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 1866-71	5.9	36
257	Azole resistance in <i>Aspergillus fumigatus</i> : a growing public health concern. <i>Current Opinion in Infectious Diseases</i> , 2013 , 26, 493-500	5.4	154
256	Amphotericin B- and voriconazole-echinocandin combinations against <i>Aspergillus</i> spp.: Effect of serum on inhibitory and fungicidal interactions. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 4656-63	5.9	23
255	Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 385-93	5.1	58
254	Invasive fungal infections in patients with chronic granulomatous disease. <i>Advances in Experimental Medicine and Biology</i> , 2013 , 764, 27-55	3.6	64
253	Favorable outcome of neonatal cerebrospinal fluid shunt-associated <i>Candida</i> meningitis with caspofungin. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 2391-3	5.9	10
252	Pharmacodynamics of anidulafungin against clinical <i>Aspergillus fumigatus</i> isolates in a nonneutropenic murine model of disseminated aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 303-8	5.9	15
251	Update on antifungal resistance in children: epidemiology and recommendations. <i>Pediatric Infectious Disease Journal</i> , 2013 , 32, 556-7	3.4	1
250	Composite survival index to compare virulence changes in azole-resistant <i>Aspergillus fumigatus</i> clinical isolates. <i>PLoS ONE</i> , 2013 , 8, e72280	3.7	16
249	ESCMID* guideline for the diagnosis and management of <i>Candida</i> diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). <i>Clinical Microbiology and Infection</i> , 2012 , 18 Suppl 7, 53-67	9.5	241
248	Simultaneous determination of the azoles voriconazole, posaconazole, isavuconazole, itraconazole and its metabolite hydroxy-itraconazole in human plasma by reversed phase ultra-performance liquid chromatography with ultraviolet detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2012 , 887-888, 79-84	3.2	35
247	ESCMID* guideline for the diagnosis and management of <i>Candida</i> diseases 2012: developing European guidelines in clinical microbiology and infectious diseases. <i>Clinical Microbiology and Infection</i> , 2012 , 18 Suppl 7, 1-8	9.5	67
246	ESCMID* guideline for the diagnosis and management of <i>Candida</i> diseases 2012: diagnostic procedures. <i>Clinical Microbiology and Infection</i> , 2012 , 18 Suppl 7, 9-18	9.5	239
245	ESCMID* guideline for the diagnosis and management of <i>Candida</i> diseases 2012: non-neutropenic adult patients. <i>Clinical Microbiology and Infection</i> , 2012 , 18 Suppl 7, 19-37	9.5	774

244	ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. <i>Clinical Microbiology and Infection</i> , 2012 , 18 Suppl 7, 38-52	9.5	206
243	ESCMID* guideline for the diagnosis and management of Candida diseases 2012: patients with HIV infection or AIDS. <i>Clinical Microbiology and Infection</i> , 2012 , 18 Suppl 7, 68-77	9.5	63
242	Importance of neutropenia for development of invasive infections at various phases of treatment for hemato-oncological diseases in children. <i>Scandinavian Journal of Infectious Diseases</i> , 2012 , 44, 355-62		5
241	Triazole fungicides can induce cross-resistance to medical triazoles in <i>Aspergillus fumigatus</i> . <i>PLoS ONE</i> , 2012 , 7, e31801	3.7	245
240	Favorable outcome of chronic disseminated candidiasis in four pediatric patients with hematological malignancies. <i>Medical Mycology</i> , 2012 , 50, 315-9	3.9	5
239	Rapid induction of multiple resistance mechanisms in <i>Aspergillus fumigatus</i> during azole therapy: a case study and review of the literature. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 10-6	5.9	161
238	Epidemiological cutoff values for azoles and <i>Aspergillus fumigatus</i> based on a novel mathematical approach incorporating cyp51A sequence analysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 2524-9	5.9	33
237	<i>Aspergillus nidulans</i> and chronic granulomatous disease: a unique host-pathogen interaction. <i>Journal of Infectious Diseases</i> , 2012 , 206, 1128-37	7	61
236	Species-specific antifungal susceptibility patterns of <i>Scedosporium</i> and <i>Pseudallescheria</i> species. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 2635-42	5.9	206
235	Extensive genetic diversity within the Dutch clinical <i>Cryptococcus neoformans</i> population. <i>Journal of Clinical Microbiology</i> , 2012 , 50, 1918-26	9.7	49
234	Molecular epidemiology of <i>Aspergillus fumigatus</i> isolates harboring the TR34/L98H azole resistance mechanism. <i>Journal of Clinical Microbiology</i> , 2012 , 50, 2674-80	9.7	103
233	Discovery of a HapE mutation that causes azole resistance in <i>Aspergillus fumigatus</i> through whole genome sequencing and sexual crossing. <i>PLoS ONE</i> , 2012 , 7, e50034	3.7	141
232	Assessment of efficacy of antifungals in experimental models of invasive aspergillosis in an era of emerging resistance: the value of real-time quantitative PCR. <i>Current Opinion in Pharmacology</i> , 2011 , 11, 486-93	5.1	10
231	The structure-function relationship of the <i>Aspergillus fumigatus</i> cyp51A L98H conversion by site-directed mutagenesis: the mechanism of L98H azole resistance. <i>Fungal Genetics and Biology</i> , 2011 , 48, 1062-70	3.9	70
230	Clinical implications of azole resistance in <i>Aspergillus fumigatus</i> , The Netherlands, 2007-2009. <i>Emerging Infectious Diseases</i> , 2011 , 17, 1846-54	10.2	326
229	Pulmonary aspergillosis caused by a pan-azole-resistant <i>Aspergillus fumigatus</i> in a 10-year-old boy. <i>Pediatric Infectious Disease Journal</i> , 2011 , 30, 268-70	3.4	11
228	Performance of the new Platelia Candida Plus assays for the diagnosis of invasive Candida infection in patients undergoing myeloablative therapy. <i>Medical Mycology</i> , 2011 , 49, 848-55	3.9	20
227	Impact of therapeutic drug monitoring of voriconazole in a pediatric population. <i>Pediatric Infectious Disease Journal</i> , 2011 , 30, 533-4	3.4	38

226	European expert opinion on the management of invasive candidiasis in adults. <i>Clinical Microbiology and Infection</i> , 2011 , 17 Suppl 5, 1-12	9.5	51
225	Calcineurin-dependent galactomannan release in <i>Aspergillus fumigatus</i> . <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2011 , 30, 551-3	5.3	3
224	Hospital point-of-use water filtration to prevent exposure to waterborne pathogens. <i>BMC Proceedings</i> , 2011 , 5,	2.3	78
223	<i>Aspergillus</i> species intrinsically resistant to antifungal agents. <i>Medical Mycology</i> , 2011 , 49 Suppl 1, S82-93.9		116
222	<i>Aspergillus fumigatus</i> cell wall components differentially modulate host TLR2 and TLR4 responses. <i>Microbes and Infection</i> , 2011 , 13, 151-9	9.3	70
221	Azole resistance in <i>Aspergillus fumigatus</i> : a new challenge in the management of invasive aspergillosis?. <i>Future Microbiology</i> , 2011 , 6, 335-47	2.9	82
220	Failure of posaconazole therapy in a renal transplant patient with invasive aspergillosis due to <i>Aspergillus fumigatus</i> with attenuated susceptibility to posaconazole. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 3564-6	5.9	34
219	Comment on: Low prevalence of resistance to azoles in <i>Aspergillus fumigatus</i> in a French cohort of patients treated for haematological malignancies. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 954-5; author reply 955	5.1	7
218	Human leukocytes kill <i>Aspergillus nidulans</i> by reactive oxygen species-independent mechanisms. <i>Infection and Immunity</i> , 2011 , 79, 767-73	3.7	33
217	A Szary cryptogram. Disseminated cryptococcal infection. <i>Netherlands Journal of Medicine</i> , 2011 , 69, 346, 349	0.5	
216	Development of azole resistance in <i>Aspergillus fumigatus</i> during azole therapy associated with change in virulence. <i>PLoS ONE</i> , 2010 , 5, e10080	3.7	128
215	Rapid diagnosis of azole-resistant aspergillosis by direct PCR using tissue specimens. <i>Journal of Clinical Microbiology</i> , 2010 , 48, 1478-80	9.7	55
214	Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 4758-64	5.9	76
213	Acute Cardiac Failure due to Intra-Atrial Mass Caused by Zygomycetes in an Immunocompromised Paediatric Patient. <i>Case Reports in Medicine</i> , 2010 , 2010, 241791	0.7	3
212	Identification of <i>Paecilomyces variotii</i> in clinical samples and settings. <i>Journal of Clinical Microbiology</i> , 2010 , 48, 2754-61	9.7	76
211	Azole resistance profile of amino acid changes in <i>Aspergillus fumigatus</i> CYP51A based on protein homology modeling. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 2425-30	5.9	144
210	Efficacy of posaconazole against three clinical <i>Aspergillus fumigatus</i> isolates with mutations in the cyp51A gene. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 860-5	5.9	105
209	Genetic variation of innate immune genes in HIV-infected african patients with or without oropharyngeal candidiasis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010 , 55, 87-94	3.1	34

208	Point-of-use filtration method for the prevention of fungal contamination of hospital water. <i>Journal of Hospital Infection</i> , 2010 , 76, 56-9	6.9	18
207	Opportunistic and systemic fungi 2010 , 1823-1852		2
206	Multiple-azole-resistant <i>Aspergillus fumigatus</i> osteomyelitis in a patient with chronic granulomatous disease successfully treated with long-term oral posaconazole and surgery. <i>Medical Mycology</i> , 2009 , 47, 217-20	3.9	119
205	The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Moulds: diagnosis and treatment. <i>Journal of Antimicrobial Chemotherapy</i> , 2009 , 63 Suppl 1, i31-5	5.1	1
204	Timing and dose of tissue plasminogen activator to prevent abscess formation after surgical treatment of secondary peritonitis in the rat. <i>Surgical Innovation</i> , 2009 , 16, 299-305	2	2
203	Azole-resistant central nervous system aspergillosis. <i>Clinical Infectious Diseases</i> , 2009 , 48, 1111-3	11.6	79
202	In vitro antifungal activity of isavuconazole against 345 mucorales isolates collected at study centers in eight countries. <i>Journal of Chemotherapy</i> , 2009 , 21, 272-81	2.3	52
201	Possible environmental origin of resistance of <i>Aspergillus fumigatus</i> to medical triazoles. <i>Applied and Environmental Microbiology</i> , 2009 , 75, 4053-7	4.8	321
200	Tissue-type plasminogen activator prevents abscess formation but does not affect healing of bowel anastomoses and laparotomy wounds in rats with secondary peritonitis. <i>Surgery</i> , 2009 , 146, 939-46	2.6	5
199	Circulating <i>Candida</i> -specific anti-mannan antibodies precede invasive candidiasis in patients undergoing myelo-ablative chemotherapy. <i>Clinical Microbiology and Infection</i> , 2009 , 15, 380-6	9.5	25
198	Trends in invasive fungal infections, with emphasis on invasive aspergillosis. <i>Clinical Microbiology and Infection</i> , 2009 , 15, 625-33	9.5	67
197	Azole-resistance in <i>Aspergillus</i> : proposed nomenclature and breakpoints. <i>Drug Resistance Updates</i> , 2009 , 12, 141-7	23.2	201
196	Dose-response relationships of three amphotericin B formulations in a non-neutropenic murine model of invasive aspergillosis. <i>Medical Mycology</i> , 2009 , 47, 802-7	3.9	9
195	Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. <i>Clinical Infectious Diseases</i> , 2009 , 48, 1441-58	11.6	300
194	International interlaboratory proficiency testing program for measurement of azole antifungal plasma concentrations. <i>Antimicrobial Agents and Chemotherapy</i> , 2009 , 53, 303-5	5.9	51
193	Value of <i>Candida</i> serum markers in patients with invasive candidiasis after myeloablative chemotherapy. <i>Diagnostic Microbiology and Infectious Disease</i> , 2009 , 64, 408-15	2.9	28
192	Azole resistance in <i>Aspergillus fumigatus</i> : a side-effect of environmental fungicide use?. <i>Lancet Infectious Diseases</i> , 2009 , 9, 789-95	25.5	444
191	Fatal consequences of an ear infection. <i>Lancet, The</i> , 2009 , 373, 1658	40	1

190 5-Flucytosine **2009**, 307-315

189	Species distribution and in vitro antifungal susceptibility of oral yeast isolates from Tanzanian HIV-infected patients with primary and recurrent oropharyngeal candidiasis. <i>BMC Microbiology</i> , 2008 , 8, 135	4.5	53
188	Both tissue-type plasminogen activator and urokinase prevent intraabdominal abscess formation after surgical treatment of peritonitis in the rat. <i>Surgery</i> , 2008 , 144, 66-73	3.6	8
187	Amphotericin B-deoxycholate overdose due to administration error in pediatric patients. <i>Medical Mycology</i> , 2008 , 46, 185-7	3.9	6
186	In vitro activities at pH 5.0 and pH 7.0 and in vivo efficacy of flucytosine against <i>Aspergillus fumigatus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2008 , 52, 4483-5	5.9	18
185	<i>Pseudomonas aeruginosa</i> as a cause of 1,3-beta-D-glucan assay reactivity. <i>Clinical Infectious Diseases</i> , 2008 , 46, 1930-1	11.6	105
184	Improved detection of circulating <i>Aspergillus</i> antigen by use of a modified pretreatment procedure. <i>Journal of Clinical Microbiology</i> , 2008 , 46, 1391-7	9.7	18
183	Drosomycin-like defensin, a human homologue of <i>Drosophila melanogaster</i> drosomycin with antifungal activity. <i>Antimicrobial Agents and Chemotherapy</i> , 2008 , 52, 1407-12	5.9	27
182	Single-dose fluconazole versus standard 2-week therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, double-blind, double-dummy trial. <i>Clinical Infectious Diseases</i> , 2008 , 47, 1270-6	11.6	28
181	<i>Aspergillus calidoustus</i> sp. nov., causative agent of human infections previously assigned to <i>Aspergillus ustus</i> . <i>Eukaryotic Cell</i> , 2008 , 7, 630-8		103
180	Gastrointestinal zygomycosis due to <i>Rhizopus microsporus</i> var. <i>rhizopodiformis</i> as a manifestation of chronic granulomatous disease. <i>Medical Mycology</i> , 2008 , 46, 491-4	3.9	17
179	Therapeutic drug monitoring of voriconazole. <i>Therapeutic Drug Monitoring</i> , 2008 , 30, 403-11	3.2	107
178	<i>Emericella quadrilineata</i> as cause of invasive aspergillosis. <i>Emerging Infectious Diseases</i> , 2008 , 14, 566-72	10.2	48
177	Disseminated aspergillosis in an adolescent with acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2008 , 51, 423-6	3	10
176	Plasminogen activator, but not systemic antibiotic therapy, prevents abscess formation in an experimental model of secondary peritonitis. <i>British Journal of Surgery</i> , 2008 , 95, 1287-93	5.3	5
175	Evaluation of cytotoxic, genotoxic and CYP450 enzymatic competition effects of Tanzanian plant extracts traditionally used for treatment of fungal infections. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2008 , 102, 515-26	3.1	24
174	Emergence of azole resistance in <i>Aspergillus fumigatus</i> and spread of a single resistance mechanism. <i>PLoS Medicine</i> , 2008 , 5, e219	11.6	536
173	Multiple-triazole-resistant aspergillosis. <i>New England Journal of Medicine</i> , 2007 , 356, 1481-3	59.2	315

172	A colorimetric and spectrophotometric method for in vitro susceptibility testing of <i>Aspergillus</i> species against caspofungin. <i>Medical Mycology</i> , 2007 , 45, 351-5	3.9	7
171	Activity and post antifungal effect of chlorpromazine and trifluoperazine against <i>Aspergillus</i> , <i>Scedosporium</i> and zygomycetes. <i>Mycoses</i> , 2007 , 50, 270-6	5.2	20
170	Tissue-type plasminogen activator prevents formation of intra-abdominal abscesses after surgical treatment of secondary peritonitis in a rat model. <i>International Journal of Colorectal Disease</i> , 2007 , 22, 819-25	3	7
169	Optimization of the cutoff value for the <i>Aspergillus</i> double-sandwich enzyme immunoassay. <i>Clinical Infectious Diseases</i> , 2007 , 44, 1329-36	11.6	149
168	Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach. <i>Journal of Antimicrobial Chemotherapy</i> , 2007 , 60, 385-93	5.1	14
167	Halo sign and improved outcome. <i>Clinical Infectious Diseases</i> , 2007 , 44, 1666-7; author reply 1667-8	11.6	13
166	Reply to Miceli and Anaissie. <i>Clinical Infectious Diseases</i> , 2007 , 44, 760-761	11.6	3
165	Aspergillosis--and a misleading sensitivity result. <i>Lancet, The</i> , 2007 , 370, 102	4.0	31
164	<i>Aspergillus</i> species identification in the clinical setting. <i>Studies in Mycology</i> , 2007 , 59, 39-46	22.2	202
163	A new <i>Aspergillus fumigatus</i> resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. <i>Antimicrobial Agents and Chemotherapy</i> , 2007 , 51, 1897-904	5.9	385
162	The Role of Conventional Diagnostic Tools. <i>Infectious Disease and Therapy</i> , 2007 , 19-40		3
161	The Role of Conventional Diagnostic Tools 2007 , 19-40		
160	Brine shrimp toxicity evaluation of some Tanzanian plants used traditionally for the treatment of fungal infections. <i>Tropical Journal of Obstetrics and Gynaecology</i> , 2006 , 4, 219-25	0.3	15
159	Primary hepatic invasive aspergillosis with progression after rituximab therapy for a post transplantation lymphoproliferative disorder. <i>Annals of Hematology</i> , 2006 , 85, 621-3	3	26
158	Molecular diagnosis of invasive aspergillosis: the long and winding road. <i>Future Microbiology</i> , 2006 , 1, 283-93	2.9	19
157	Issues with galactomannan testing. <i>Medical Mycology</i> , 2006 , 44, S179-S183	3.9	35
156	1,3-beta-D-glucan in patients receiving intravenous amoxicillin-clavulanic acid. <i>New England Journal of Medicine</i> , 2006 , 354, 2834-5	59.2	89
155	In vitro release by <i>Aspergillus fumigatus</i> of galactofuranose antigens, 1,3-beta-D-glucan, and DNA, surrogate markers used for diagnosis of invasive aspergillosis. <i>Journal of Clinical Microbiology</i> , 2006 , 44, 1711-8	9.7	62

154	Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt. <i>Clinical Infectious Diseases</i> , 2006 , 43, 1031-9	11.6	2
153	Paradoxical increase in circulating <i>Aspergillus</i> antigen during treatment with caspofungin in a patient with pulmonary aspergillosis. <i>Clinical Infectious Diseases</i> , 2006 , 43, e23-5	11.6	40
152	<i>Alternaria</i> infectoria phaeohyphomycosis in a renal transplant patient. <i>Medical Mycology</i> , 2006 , 44, 379-82	3.9	17
151	Non-culture-based diagnostics for opportunistic fungi. <i>Infectious Disease Clinics of North America</i> , 2006 , 20, 711-27, viii	6.5	61
150	The concentration-dependent nature of in vitro amphotericin B-itraconazole interaction against <i>Aspergillus fumigatus</i> : isobolographic and response surface analysis of complex pharmacodynamic interactions. <i>International Journal of Antimicrobial Agents</i> , 2006 , 28, 439-49	14.3	26
149	Antifungal activity of some Tanzanian plants used traditionally for the treatment of fungal infections. <i>Journal of Ethnopharmacology</i> , 2006 , 108, 124-32	5	111
148	Oral manifestations of HIV infection in children and adults receiving highly active anti-retroviral therapy [HAART] in Dar es Salaam, Tanzania. <i>BMC Oral Health</i> , 2006 , 6, 12	3.7	66
147	<i>Legionella pneumophila</i> in commercial bottled mineral water. <i>FEMS Immunology and Medical Microbiology</i> , 2006 , 47, 42-4		7
146	A peritonitis model with low mortality and persisting intra-abdominal abscesses. <i>International Journal of Experimental Pathology</i> , 2006 , 87, 361-8	2.8	17
145	Involvement of glycosaminoglycans in the attachment of pneumococci to nasopharyngeal epithelial cells. <i>Microbes and Infection</i> , 2006 , 8, 316-22	9.3	40
144	Toll-like receptor 4 Asp299Gly/Thr399Ile polymorphisms are a risk factor for <i>Candida</i> bloodstream infection. <i>European Cytokine Network</i> , 2006 , 17, 29-34	3.3	115
143	Advances in diagnostic testing. <i>Medical Mycology</i> , 2005 , 43 Suppl 1, S121-4	3.9	24
142	Clinical implications of environmental sources for <i>Aspergillus</i> . <i>Medical Mycology</i> , 2005 , 43 Suppl 1, S59-65	6.9	41
141	Cytokine responses and regulation of interferon-gamma release by human mononuclear cells to <i>Aspergillus fumigatus</i> and other filamentous fungi. <i>Medical Mycology</i> , 2005 , 43, 613-21	3.9	45
140	Assessing in vitro combinations of antifungal drugs against yeasts and filamentous fungi: comparison of different drug interaction models. <i>Medical Mycology</i> , 2005 , 43, 133-52	3.9	80
139	Comparison of visual 24-hour and spectrophotometric 48-hour MICs to CLSI reference microdilution MICs of fluconazole, itraconazole, posaconazole, and voriconazole for <i>Candida</i> spp.: a collaborative study. <i>Journal of Clinical Microbiology</i> , 2005 , 43, 4535-40	9.7	30
138	Bifidobacterial lipoglycan as a new cause for false-positive platelia <i>Aspergillus</i> enzyme-linked immunosorbent assay reactivity. <i>Journal of Clinical Microbiology</i> , 2005 , 43, 3925-31	9.7	75
137	Efficacy and pharmacodynamics of flucytosine monotherapy in a nonneutropenic murine model of invasive aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2005 , 49, 4220-6	5.9	21

136	Successful treatment of Fusarium keratitis with cornea transplantation and topical and systemic voriconazole. <i>Clinical Infectious Diseases</i> , 2005 , 40, e110-2	11.6	57
135	Influence of endogenous pro-inflammatory cytokines on neutrophil-mediated damage of <i>Candida albicans</i> pseudohyphae, quantified in a modified tetrazolium dye assay. <i>Medical Mycology</i> , 2005 , 43, 551-3	9.9	8
134	International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of <i>Candida</i> spp. to fluconazole, itraconazole, posaconazole, and voriconazole. <i>Journal of Clinical Microbiology</i> , 2005 , 43, 3884-9	9.7	101
133	Duration of antibiotic treatment: are even numbers odd?. <i>Journal of Antimicrobial Chemotherapy</i> , 2005 , 56, 441-2	5.1	5
132	Relationship between in vitro activities of amphotericin B and flucytosine and pH for clinical yeast and mold isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2005 , 49, 3341-6	5.9	16
131	Interlaboratory comparison of results of susceptibility testing with caspofungin against <i>Candida</i> and <i>Aspergillus</i> species. <i>Journal of Clinical Microbiology</i> , 2004 , 42, 3475-82	9.7	163
130	Detection of the <i>Candida</i> antigen mannan in cerebrospinal fluid specimens from patients suspected of having <i>Candida</i> meningitis. <i>Journal of Clinical Microbiology</i> , 2004 , 42, 867-70	9.7	37
129	Utility of <i>Aspergillus</i> antigen detection in specimens other than serum specimens. <i>Clinical Infectious Diseases</i> , 2004 , 39, 1467-74	11.6	145
128	In vitro interactions between amphotericin B, itraconazole, and flucytosine against 21 clinical <i>Aspergillus</i> isolates determined by two drug interaction models. <i>Antimicrobial Agents and Chemotherapy</i> , 2004 , 48, 2007-13	5.9	31
127	Potent synergistic in vitro interaction between nonantimicrobial membrane-active compounds and itraconazole against clinical isolates of <i>Aspergillus fumigatus</i> resistant to itraconazole. <i>Antimicrobial Agents and Chemotherapy</i> , 2004 , 48, 1335-43	5.9	52
126	Two patients with cryptococcal meningitis and idiopathic CD4 lymphopenia: defective cytokine production and reversal by recombinant interferon- gamma therapy. <i>Clinical Infectious Diseases</i> , 2004 , 39, e83-7	11.6	88
125	Routine use of a commercial test, GLABRATA RTT, for rapid identification of <i>Candida glabrata</i> in six laboratories. <i>Journal of Clinical Microbiology</i> , 2004 , 42, 4870-2	9.7	16
124	Effect of pH on the in vitro activities of amphotericin B, itraconazole, and flucytosine against <i>Aspergillus</i> isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2004 , 48, 3147-50	5.9	25
123	Validating PCR for detecting invasive aspergillosis. <i>British Journal of Haematology</i> , 2004 , 127, 235-6	4.5	10
122	Fatal hemorrhagic pneumonia caused by infection due to <i>Kytococcus sedentarius</i> --a pathogen or passenger?. <i>Annals of Hematology</i> , 2004 , 83, 447-9	3	18
121	Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. <i>Lancet Infectious Diseases</i> , 2004 , 4, 349-57	25.5	400
120	Bifidobacterium lipoteichoic acid and false ELISA reactivity in aspergillus antigen detection. <i>Lancet</i> , 2004 , 363, 325-7	40	98
119	Susceptibility testing of sequential isolates of <i>Aspergillus fumigatus</i> recovered from treated patients. <i>Journal of Medical Microbiology</i> , 2004 , 53, 129-134	3.2	34

118	Evaluation of a polymerase chain reaction reverse hybridization line probe assay for the detection and identification of medically important fungi in bronchoalveolar lavage fluids. <i>Medical Mycology</i> , 2003 , 41, 65-74	3.9	10
117	Use of turbidimetric growth curves for early determination of antifungal drug resistance of filamentous fungi. <i>Journal of Clinical Microbiology</i> , 2003 , 41, 4718-25	9.7	29
116	Molecular epidemiology of <i>Aspergillus fumigatus</i> isolates recovered from water, air, and patients shows two clusters of genetically distinct strains. <i>Journal of Clinical Microbiology</i> , 2003 , 41, 4101-6	9.7	111
115	Forum report: issues in the design of trials of drugs for the treatment of invasive aspergillosis. <i>Clinical Infectious Diseases</i> , 2003 , 36, S113-6	11.6	7
114	In vitro susceptibilities of zygomycetes to conventional and new antifungals. <i>Journal of Antimicrobial Chemotherapy</i> , 2003 , 51, 45-52	5.1	246
113	Forum report: issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients. <i>Clinical Infectious Diseases</i> , 2003 , 36, S117-22	11.6	48
112	. <i>Pediatric Infectious Disease Journal</i> , 2003 , 22, 576	3.4	
111	Cytokine release in healthy donors and patients with chronic granulomatous disease upon stimulation with <i>Aspergillus fumigatus</i> . <i>Scandinavian Journal of Infectious Diseases</i> , 2003 , 35, 482-7		33
110	Cryptococcal meningitis in a child with acute lymphoblastic leukemia. <i>Pediatric Infectious Disease Journal</i> , 2003 , 22, 576	3.4	7
109	Antifungal activity of nonantifungal drugs. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2003 , 22, 397-407	5.3	41
108	Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). <i>Clinical Microbiology and Infection</i> , 2003 , 9, 467-74	9.5	116
107	Two cases of subcutaneous <i>Scedosporium apiospermum</i> infection treated with voriconazole. <i>Clinical Microbiology and Infection</i> , 2003 , 9, 750-3	9.5	31
106	Culture and infection control. <i>Lancet, The</i> , 2003 , 361, 1657	4.0	1
105	Should we routinely disinfect floors?. <i>Journal of Hospital Infection</i> , 2003 , 53, 150	6.9	4
104	In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical <i>Scedosporium prolificans</i> isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2003 , 47, 106-17	5.9	204
103	Invasive infections due to <i>Apophysomyces elegans</i> . <i>Mayo Clinic Proceedings</i> , 2003 , 78, 252-3	6.4	6
102	In vitro activity of amphotericin B, itraconazole, terbinafine and 5-fluocytosine against <i>Exophiala spinifera</i> and evaluation of post-antifungal effects. <i>Medical Mycology</i> , 2003 , 41, 301-7	3.9	19
101	Evaluation of the post-antifungal effect (PAFE) of amphotericin B and nystatin against 30 zygomycetes using two different media. <i>Journal of Antimicrobial Chemotherapy</i> , 2003 , 52, 65-70	5.1	13

100	Introduction the Forum Report on Advances in the Design of Antifungal Clinical Trials. <i>Clinical Infectious Diseases</i> , 2003 , 36, S112-S112	11.6	
99	Forum report: issues in the evaluation of diagnostic tests, use of historical controls, and merits of the current multicenter collaborative groups. <i>Clinical Infectious Diseases</i> , 2003 , 36, S123-7	11.6	9
98	Activity of posaconazole in treatment of experimental disseminated zygomycosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2003 , 47, 3647-50	5.9	141
97	Keratitis caused by <i>Scedosporium apiospermum</i> successfully treated with a cornea transplant and voriconazole. <i>Journal of Clinical Microbiology</i> , 2003 , 41, 2261-4	9.7	54
96	Treatment of intra-abdominal abscesses caused by <i>Candida albicans</i> with antifungal agents and recombinant murine granulocyte colony-stimulating factor. <i>Antimicrobial Agents and Chemotherapy</i> , 2003 , 47, 3688-93	5.9	8
95	In vitro activity of amphotericin B and itraconazole in combination with flucytosine, sulfadiazine and quinolones against <i>Exophiala spinifera</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2003 , 51, 1297-300	5.1	22
94	<i>Aspergillus fumigatus</i> evades immune recognition during germination through loss of toll-like receptor-4-mediated signal transduction. <i>Journal of Infectious Diseases</i> , 2003 , 188, 320-6	7	251
93	Combination therapy for keratitis by the fungus <i>Scedosporium</i> . <i>Cornea</i> , 2003 , 22, 92	3.1	6
92	Preventing fungal infections in chronic granulomatous disease. <i>New England Journal of Medicine</i> , 2003 , 349, 1190-1; author reply 1190-1	59.2	3
91	<i>Aspergillus galactomannan</i> antigen levels in allogeneic haematopoietic stem cell transplant recipients given total parenteral nutrition. <i>Transplant Infectious Disease</i> , 2002 , 4, 64-5	2.7	14
90	Case Reports. Chronic and acute <i>Aspergillus</i> meningitis. <i>Mycoses</i> , 2002 , 45, 504-11	5.2	21
89	Comparison of the Etest and the sensititre colorimetric methods with the NCCLS proposed standard for antifungal susceptibility testing of <i>Aspergillus</i> species. <i>Journal of Clinical Microbiology</i> , 2002 , 40, 2876-85	9.7	49
88	Nationwide survey of in vitro activities of itraconazole and voriconazole against clinical <i>Aspergillus fumigatus</i> isolates cultured between 1945 and 1998. <i>Journal of Clinical Microbiology</i> , 2002 , 40, 2648-50	9.7	81
87	In vitro synergistic interaction between amphotericin B and pentamidine against <i>Scedosporium prolificans</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2002 , 46, 3323-6	5.9	38
86	In vitro activities of new and conventional antifungal agents against clinical <i>Scedosporium</i> isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2002 , 46, 62-8	5.9	205
85	Identification of four distinct genotypes of <i>Candida dubliniensis</i> and detection of microevolution in vitro and in vivo. <i>Journal of Clinical Microbiology</i> , 2002 , 40, 556-74	9.7	70
84	Differentiation of <i>Aspergillus ustus</i> strains by random amplification of polymorphic DNA. <i>Journal of Clinical Microbiology</i> , 2002 , 40, 2231-3	9.7	13
83	In vitro susceptibilities of zygomycetes to combinations of antimicrobial agents. <i>Antimicrobial Agents and Chemotherapy</i> , 2002 , 46, 2708-11	5.9	69

82	Multidrug resistance in <i>Aspergillus fumigatus</i> . <i>New England Journal of Medicine</i> , 2002 , 347, 2173-4	59.2	75
81	Efficacy of antifungal therapy in a nonneutropenic murine model of zygomycosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2002 , 46, 1953-9	5.9	47
80	In vitro susceptibilities of Zygomycota to polyenes. <i>Journal of Antimicrobial Chemotherapy</i> , 2002 , 49, 741-4	5.1	16
79	Comparison of fractional inhibitory concentration index with response surface modeling for characterization of in vitro interaction of antifungals against itraconazole-susceptible and -resistant <i>Aspergillus fumigatus</i> isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2002 , 46, 702-7	5.9	46
78	In vitro interaction of flucytosine combined with amphotericin B or fluconazole against thirty-five yeast isolates determined by both the fractional inhibitory concentration index and the response surface approach. <i>Antimicrobial Agents and Chemotherapy</i> , 2002 , 46, 2982-9	5.9	65
77	Method for measuring postantifungal effect in <i>Aspergillus</i> species. <i>Antimicrobial Agents and Chemotherapy</i> , 2002 , 46, 1960-5	5.9	22
76	In vitro activities of pentamidine, pyrimethamine, trimethoprim, and sulfonamides against <i>Aspergillus</i> species. <i>Antimicrobial Agents and Chemotherapy</i> , 2002 , 46, 2029-31	5.9	21
75	Contamination of hospital water with <i>Aspergillus fumigatus</i> and other molds. <i>Clinical Infectious Diseases</i> , 2002 , 34, 1159-60	11.6	51
74	Methodological issues related to antifungal drug interaction modelling for filamentous fungi. <i>Reviews in Medical Microbiology</i> , 2002 , 13, 101-117	1.1	11
73	Recent progress in the diagnosis of fungal infections in the immunocompromised host. <i>Drug Resistance Updates</i> , 2002 , 5, 3-10	23.2	26
72	Case Reports. Chronic and acute <i>Aspergillus meningitis</i> - Falldarstellungen. Chronische und akute <i>Aspergillus-Meningitis</i> . <i>Mycoses</i> , 2002 , 45, 504-511	5.2	25
71	Critical assessment of issues in the diagnosis of invasive aspergillosis. <i>Clinical Microbiology and Infection</i> , 2001 , 7 Suppl 2, 32-7	9.5	27
70	Comparison of spectrophotometric and visual readings of NCCLS method and evaluation of a colorimetric method based on reduction of a soluble tetrazolium salt, 2,3-bis [2-methoxy-4-nitro-5-[(sulfenylamino) carbonyl]-2H-tetrazolium-hydroxide], for antifungal susceptibility testing of <i>Aspergillus</i> species. <i>Journal of Clinical Microbiology</i> , 2001 , 39, 4256-63	9.7	67
69	Colorimetric assay for antifungal susceptibility testing of <i>Aspergillus</i> species. <i>Journal of Clinical Microbiology</i> , 2001 , 39, 3402-8	9.7	142
68	Involvement of CD14 and toll-like receptors in activation of human monocytes by <i>Aspergillus fumigatus</i> hyphae. <i>Infection and Immunity</i> , 2001 , 69, 2402-6	3.7	200
67	Analysis of growth characteristics of filamentous fungi in different nutrient media. <i>Journal of Clinical Microbiology</i> , 2001 , 39, 478-84	9.7	131
66	Current management of fungal infections. <i>Drugs</i> , 2001 , 61 Suppl 1, 13-25	12.1	64
65	Recovery of filamentous fungi from water in a paediatric bone marrow transplantation unit. <i>Journal of Hospital Infection</i> , 2001 , 47, 143-8	6.9	83

64	Prevention of invasive aspergillosis in AIDS by sulfamethoxazole. <i>Aids</i> , 2001 , 15, 1067-8	3.5	7
63	Hospital sources of <i>Aspergillus</i> : New routes of transmission?. <i>Revista Iberoamericana De Micologia</i> , 2001 , 18, 156-62	1.6	25
62	Combination chemotherapy for the treatment of invasive infections by <i>Scedosporium prolificans</i> . <i>Clinical Microbiology and Infection</i> , 2000 , 6, 336-7	9.5	33
61	In vitro susceptibilities of 11 clinical isolates of <i>Exophiala</i> species to six antifungal drugs. <i>Mycoses</i> , 2000 , 43, 309-12	5.2	27
60	Microbiological diagnosis of invasive fungal infections in transplant recipients. <i>Transplant Infectious Disease</i> , 2000 , 2, 80-7	2.7	32
59	Atypical presentation of <i>Madurella mycetomatis</i> mycetoma in a renal transplant patient. <i>Transplant Infectious Disease</i> , 2000 , 2, 96-8	2.7	19
58	<i>Aspergillus</i> tracheobronchitis after allogeneic bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 2000 , 26, 1131-2	4.4	17
57	One-year prevalence of <i>Candida dubliniensis</i> in a Dutch university hospital. <i>Journal of Clinical Microbiology</i> , 2000 , 38, 3139-40	9.7	15
56	Invasive aspergillosis. <i>Medical Mycology</i> , 2000 , 38, 215-224	3.9	16
55	In vitro interaction of terbinafine with itraconazole against clinical isolates of <i>Scedosporium prolificans</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2000 , 44, 470-2	5.9	88
54	Cervical spinal epidural abscess due to group B streptococcus in a previously healthy elderly male. <i>Scandinavian Journal of Infectious Diseases</i> , 2000 , 32, 577		5
53	<i>Acremonium strictum</i> fungaemia in a paediatric patient with acute leukaemia. <i>Scandinavian Journal of Infectious Diseases</i> , 2000 , 32, 442-4		30
52	Failure to detect circulating <i>Aspergillus</i> markers in a patient with chronic granulomatous disease and invasive aspergillosis. <i>Journal of Clinical Microbiology</i> , 2000 , 38, 3900-1	9.7	83
51	Comparison of NCCLS and 3-(4,5-dimethyl-2-Thiazyl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) methods of in vitro susceptibility testing of filamentous fungi and development of a new simplified method. <i>Journal of Clinical Microbiology</i> , 2000 , 38, 2949-54	9.7	175
50	Clinical applications of non-culture based methods for the diagnosis and management of opportunistic and endemic mycoses. <i>Medical Mycology</i> , 2000 , 38, 161-171	3.9	3
49	Fungal contamination of tobacco and marijuana. <i>JAMA - Journal of the American Medical Association</i> , 2000 , 284, 2875	27.4	43
48	<i>Candida dubliniensis</i> candidemia in patients with chemotherapy-induced neutropenia and bone marrow transplantation. <i>Emerging Infectious Diseases</i> , 1999 , 5, 150-3	10.2	113
47	Comparative study of seven commercial yeast identification systems. <i>Journal of Clinical Pathology</i> , 1999 , 52, 271-3	3.9	60

46	Epidemiology of nosocomial fungal infections: invasive aspergillosis and the environment. <i>Diagnostic Microbiology and Infectious Disease</i> , 1999 , 34, 221-7	2.9	91
45	Faucet aerators: A source of patient colonization with <i>Stenotrophomonas maltophilia</i> . <i>American Journal of Infection Control</i> , 1999 , 27, 459-60	3.8	7
44	Perianal ulcer. <i>Lancet, The</i> , 1999 , 353, 1881	4.0	6
43	Antibacterial activity of hyperforin from St John's wort. <i>Lancet, The</i> , 1999 , 354, 777	4.0	6
42	<i>Aspergillus meningitis: diagnosis by non-culture-based microbiological methods and management. Journal of Clinical Microbiology</i> , 1999 , 37, 1186-9	9.7	115
41	Invasive aspergillosis caused by <i>Aspergillus ustus</i> : case report and review. <i>Journal of Clinical Microbiology</i> , 1999 , 37, 1606-9	9.7	70
40	Invasive aspergillosis in two patients with Pearson syndrome. <i>Pediatric Infectious Disease Journal</i> , 1999 , 18, 739-41	3.4	11
39	Prevalence of antibodies to <i>Histoplasma capsulatum</i> among Dutch speleologists. <i>Journal of Infection</i> , 1998 , 37, 200-1	18.9	
38	Microgranulomatous aspergillosis in a patient with chronic granulomatous disease: cure with voriconazole. <i>Clinical Infectious Diseases</i> , 1998 , 26, 996-7	11.6	18
37	Successful treatment with voriconazole of invasive aspergillosis in chronic granulomatous disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1998 , 157, 1694-6	10.2	66
36	Detection of <i>Aspergillus fumigatus</i> PCR products by a microtitre plate based DNA hybridisation assay. <i>Journal of Clinical Pathology</i> , 1998 , 51, 617-20	3.9	17
35	In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental <i>Aspergillus fumigatus</i> isolates. <i>Journal of Antimicrobial Chemotherapy</i> , 1998 , 42, 389-92	5.1	66
34	Resistance of <i>aspergillus fumigatus</i> to itraconazole. <i>Scandinavian Journal of Infectious Diseases</i> , 1998 , 30, 642-3		4
33	Nosocomial outbreak of colonization and infection with <i>Stenotrophomonas maltophilia</i> in preterm infants associated with contaminated tap water. <i>Epidemiology and Infection</i> , 1998 , 120, 251-6	4.3	57
32	Efficacy of LY303366 against amphotericin B-susceptible and -resistant <i>Aspergillus fumigatus</i> in a murine model of invasive aspergillosis. <i>Antimicrobial Agents and Chemotherapy</i> , 1998 , 42, 873-8	5.9	88
31	Detection of antigen in sera of patients with invasive aspergillosis: intra- and interlaboratory reproducibility. The Dutch Interuniversity Working Party for Invasive Mycoses. <i>Journal of Clinical Microbiology</i> , 1998 , 36, 1612-6	9.7	50
30	Diagnostic and Therapeutic Strategies for Invasive Aspergillosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 1997 , 18, 203-215	3.9	18
29	Needleless Intravenous Systems. <i>Infection Control and Hospital Epidemiology</i> , 1997 , 18, 536-537	2	1

28	Pseudo-Outbreak of Multiresistant <i>Pseudomonas aeruginosa</i> in a Hematology Unit. <i>Infection Control and Hospital Epidemiology</i> , 1997 , 18, 128-131	2	14
27	Two strategies for managing invasive aspergillosis: a decision analysis. <i>Clinical Infectious Diseases</i> , 1997 , 25, 1148-54	11.6	45
26	<i>Clostridium septicum</i> sepsis and neutropenic enterocolitis in a patient treated with intensive chemotherapy for acute myeloid leukemia. <i>Annals of Hematology</i> , 1997 , 74, 143-7	3	14
25	Serial monitoring of <i>Aspergillus</i> antigen in the early diagnosis of invasive aspergillosis. Preliminary investigations with two examples. <i>Infection</i> , 1997 , 25, 86-9	5.8	66
24	Oral terbinafine for treatment of pulmonary <i>Pseudallescheria boydii</i> infection refractory to itraconazole therapy. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1997 , 16, 26-8	5.3	25
23	Specificity of a sandwich enzyme-linked immunosorbent assay for detecting <i>Aspergillus galactomannan</i> . <i>Journal of Clinical Microbiology</i> , 1997 , 35, 257-60	9.7	167
22	Pseudo-outbreak of multiresistant <i>Pseudomonas aeruginosa</i> in a hematology unit. <i>Infection Control and Hospital Epidemiology</i> , 1997 , 18, 128-31	2	8
21	Carriage of <i>Staphylococcus haemolyticus</i> among healthcare workers. <i>Journal of Hospital Infection</i> , 1996 , 32, 320-1	6.9	1
20	Prospects for the early diagnosis of invasive aspergillosis in the immunocompromised patient. <i>Reviews in Medical Microbiology</i> , 1996 , 7, 105-114	1.1	21
19	Immunoperoxidase staining for identification of <i>Aspergillus</i> species in routinely processed tissue sections. <i>Journal of Clinical Pathology</i> , 1996 , 49, 798-801	3.9	37
18	High-dose itraconazole for the treatment of cerebral aspergillosis. <i>Clinical Infectious Diseases</i> , 1996 , 23, 1196-7	11.6	9
17	Genotypic characterization of sequential <i>Aspergillus fumigatus</i> isolates from patients with cystic fibrosis. <i>Journal of Clinical Microbiology</i> , 1996 , 34, 2595-7	9.7	49
16	Phylogenetic relationships of five species of <i>Aspergillus</i> and related taxa as deduced by comparison of sequences of small subunit ribosomal RNA. <i>Medical Mycology</i> , 1995 , 33, 185-90	3.9	24
15	Clinical evaluation and reproducibility of the Pastorex <i>Aspergillus</i> antigen latex agglutination test for diagnosing invasive aspergillosis. <i>Journal of Clinical Pathology</i> , 1995 , 48, 474-6	3.9	35
14	Interrepeat Fingerprinting of Third-Generation Cephalosporin-Resistant <i>Enterobacter cloacae</i> Isolated during an Outbreak in a Neonatal Intensive Care Unit. <i>Infection Control and Hospital Epidemiology</i> , 1995 , 16, 25-29	2	25
13	Severe human psittacosis requiring artificial ventilation: case report and review. <i>Clinical Infectious Diseases</i> , 1995 , 20, 440-2	11.6	29
12	Septic shock caused by group G beta-haemolytic streptococci as presenting symptom of acute myeloid leukaemia. <i>Netherlands Journal of Medicine</i> , 1995 , 46, 153-5	0.5	9
11	Comparison of antigen detection and PCR assay using bronchoalveolar lavage fluid for diagnosing invasive pulmonary aspergillosis in patients receiving treatment for hematological malignancies. <i>Journal of Clinical Microbiology</i> , 1995 , 33, 3150-3	9.7	119

10	Sandwich enzyme-linked immunosorbent assay compared with Pastorex latex agglutination test for diagnosing invasive aspergillosis in immunocompromised patients. <i>Journal of Clinical Microbiology</i> , 1995 , 33, 1912-4	9.7	132
9	Interrepeat fingerprinting of third-generation cephalosporin-resistant <i>Enterobacter cloacae</i> isolated during an outbreak in a neonatal intensive care unit. <i>Infection Control and Hospital Epidemiology</i> , 1995 , 16, 25-9	2	14
8	Endophthalmitis as presenting symptom of group G streptococcal endocarditis. <i>Infection</i> , 1994 , 22, 56-7	5.8	19
7	Amphotericin B versus amphotericin B plus 5-flucytosine: poor results in the treatment of proven systemic mycoses in neutropenic patients. <i>Infection</i> , 1994 , 22, 81-5	5.8	50
6	Polymerase chain reaction as a diagnostic tool for invasive aspergillosis: evaluation in bronchoalveolar lavage fluid from low risk patients. <i>Serodiagnosis and Immunotherapy in Infectious Disease</i> , 1994 , 6, 203-208		12
5	General primer-mediated PCR for detection of <i>Aspergillus</i> species. <i>Journal of Clinical Microbiology</i> , 1994 , 32, 1710-7	9.7	139
4	Cross-infection with <i>Pseudomonas aeruginosa</i> in a neonatal intensive care unit characterized by polymerase chain reaction fingerprinting. <i>Pediatric Infectious Disease Journal</i> , 1993 , 12, 1027-9	3.4	6
3	Hygiene, skin infections and types of water supply in Venda, South Africa. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 1991 , 85, 681-4	2	11
2	Galactomannan and Anti- <i>Aspergillus</i> Antibody Detection for the Diagnosis of Invasive Aspergillosis		363-372 2
1	Evaluation of a polymerase chain reaction reverse hybridization line probe assay for the detection and identification of medically important fungi in bronchoalveolar lavage fluids		1